F4 Pharma GmbH has an experienced core management team in place, which is headed by a pharmaceutical executive with long-standing R&D and business experience:
- Mag. Thomas Steiner is an entrepreneur who spent most of his career in multinationals. In 2000 he founded his own company, MChE Trading, which is supporting start-ups and high-tech business in various fields ranging from bio-tech to the air and space industry. He co-founded the bio-tech company FIBREX in 2001 which he headed as CEO until its financing by venture capital in 2005. In March 2013 he decided to acquire the assets of Fibrex and reposition FX06 as potential treatment of severely ill patients in orphan and super orphan indications.
- Petra Wülfroth, PhD, has long lasting management experience in Pharma and Biotech R&D in small, medium-sized and big companies. As Managing Director and founder of accella advisors GmbH, a consultancy company for start-ups in the Life Science area, she is serving as expert and evaluator for business concepts in the Life Science area since more than 20 years. She is also accredited Innovation Mentor at Innosuisse, the Swiss Federal Innovation Agency. For MChE GmbH / F4 Pharma GmbH she has developed the business and development strategy for FX06 and supervised the scientific, medical and regulatory activities.